News >

Frontline Maintenance Niraparib Improves PFS in Ovarian Cancer

Gina Columbus @ginacolumbusonc
Published: Monday, Jul 15, 2019

Hal Barron, MD

Hal Barron, MD

Niraparib (Zejula) as a maintenance treatment demonstrated a statistically significant improvement in progression-free survival (PFS) compared with placebo in patients with ovarian cancer following first-line platinum-based chemotherapy, regardless of biomarker status, meeting the primary endpoint of the phase III PRIMA (ENGOT-OV26/GOG-3012) trial.1

Under the Prescription Drug User Fee Act, the FDA must make a decision on the application by October 24, 2019.

References

  1. GSK announces positive headline results in Phase 3 PRIMA study of ZEJULA (niraparib) for patients with ovarian cancer in the first line maintenance setting. GlaxoSmithKline. Published July 15, 2019. https://bit.ly/2YTFO6h. Accessed July 15, 2019.
  2. U.S. Food and Drug Administration accepts GSK’s application for ZEJULA (niraparib) in late stage ovarian cancer with priority review. GlaxoSmithKline. Published June 24, 2019. https://bit.ly/2Le2Alq. Accessed June 24, 2019.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication
x